Results

Total Results: 658 records

Showing results for "mentioned".

241. Multidisciplinary Postacute Rehabilitation for Moderate to Severe Traumatic Brain Injury in Adults Disposition of Comments (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/traumatic-brain-injury-rehabilitation_disposition-comments.pdf
     October 07, 2012 - Peer Reviewer #7 Introduction On page iii of the ES, stakeholders are mentioned, but then I did not find … There are several important issues mentioned in the discussion. … to the Discussion section of the ES and full report to further address future research needs and mentioned … The timing of treatment benefits is specifically mentioned, and the length of time benefits are sustained … , one would likely get widespread endorsement of one or more of the outcomes mentioned above.

242. Disposition of Comments for Evidence Report 224 Omega-3 Fatty Acids (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/omega-3-maternity_disposition-comments.pdf
     October 12, 2016 - We mentioned in our list of study limitations that many interventions described as n-3 FA (especially … found in these sources were derived from dietary intake of plants, nuts, or algae and other sources mentioned … I would revise to the following because they are mentioned in the summary of studies and psychologists … so far, 2 to indicate the need of major homogeneity in studies (FA status, haplotypes, as already mentioned

243. Disposition of Comments Report for Treatments for Ankyloglossia and Ankyloglossia With Concomitant Lip-Tie (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ankyloglossia_disposition-comments.pdf
     May 04, 2015 - This was mentioned on Page 14 Lines 25/26 in the table.

244. Disposition of Comments Report for The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-197-fractional-exhaled-nitric-oxide-disposition-comments.pdf
     December 20, 2017 - FeNO is usually low in obese patients and although this is mentioned in a line statement, nothing was

245. Medical Therapies for Children With Autism Spectrum Disorder—An Updaterum Disorder--An Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/asd-medical-disposition.pdf
     May 26, 2017 - I strongly recommend that this be mentioned, even though little data are currently available, since … many other approaches with little data are mentioned there.

246. PKU Surveillance Assessment_CER 56_Low (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/phenylketonuria_surveillance.pdf
     January 15, 2013 - One of the references mentioned by this expert was a guideline recently issued for the use of sapropterin … affect birth outcomes.9 Not relevant 4/4 experts stated that there was no new evidence but one mentioned … One expert mentioned a BioMarin PKU-016 study that measures outcomes of tetrahydrobiopterin in relation

247. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/type-2-diabetes-medications-update_research-protocol.pdf
     April 06, 2010 - We are also considering for inclusion studies that compare one of the metformin combinations mentioned … We are tallying, but not including, studies that compare the metformin combinations mentioned above

248. Glaucoma-Treatment Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/glaucoma-treatment_research-protocol.pdf
     November 16, 2010 - Preparations of the above-mentioned agents by their trade and generic/chemical names are included in … participants might not be possible with some of the interventions being examined, but it will be noted when mentioned

249. Use of Telehealth During the COVID-19 Era (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/telehealth-covid-19-disposition-comments.pdf
     January 03, 2023 - since 2020, there are several barriers related to the provision and use of telehealth that were not mentioned

250. Disposition of Comments CER 219 Antipsychotics for the Prevention and Treatment of Delirium (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/delirium-disposition-comments.pdf
     September 03, 2019 - Disposition of Comments CER 219 Antipsychotics for the Prevention and Treatment of Delirium Comparative Effectiveness Review Disposition of Comments Report Research Review Title: Antipsychotics for the Prevention and Treatment of Delirium Draft review available for public comment from March 4, 2019 to April 1, 20…

251. Cell-Free-Dna-Appendix-C-Prepub-Final (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cell-free-dna-appendix-c-prepub-final.xlsx
     January 01, 2025 - all participants undergoing the exam were offered the MCST, but a random or consecutive sample is not mentioned … Yes Yes Probably yes No NA Unclear Protocol indicates authors were going to use ROB 2, but it is not mentioned … authors self-funded the research or if there were other sources of support that are not explicitly mentioned

252. Cell-Free-Dna-Final-App-C (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cell-free-dna-final-app-c.xlsx
     January 01, 2025 - all participants undergoing the exam were offered the MCST, but a random or consecutive sample is not mentioned … Yes Yes Probably yes No NA Unclear Protocol indicates authors were going to use ROB 2, but it is not mentioned … authors self-funded the research or if there were other sources of support that are not explicitly mentioned

253. CER 218 Disposition of Comments: Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-218-osteoporosis-disposition-comments.pdf
     April 23, 2019 - ASBMR) Data are available of an increased risk of AFF and ONJ with longer term denosumab which isn't mentioned … following with a bisphosphonate will cause rapid turnover and increased fracture risk ‐ this should be mentioned

254. Disposition of Comments_Comparative Effectiveness Review No. 263: Management of Postpartum Hypertensive Disorders of Pregnancy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/hypertensive-disorders-pregnancy-disposition-comments.pdf
     May 31, 2023 - Disposition of Comments_Comparative Effectiveness Review No. 263: Management of Postpartum Hypertensive Disorders of Pregnancy Comparative Effectiveness Review Disposition of Comments Report Research Title: Management of Postpartum Hypertensive Disorders of Pregnancy The draft report was available fo…

255. Disposition of Comments for CER 175 Total Worker Health (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/worker-health_disposition-comments.pdf
     May 31, 2016 - 2016 20 Commentator and Affiliation Section Comment Response TEP Reviewer #1 General You mentioned … All of the contextual factors mentioned by the authors were abstracted and considered in this review

256. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/treatment-resistant-depression_disposition-comments.pdf
     September 01, 2011 - Peer Reviewer #5 Results It is not clear to me why some interventions were excluded or not even mentioned … for treatment resistant depression in several open trials with RCTs underway yet this is not even mentioned … We have created a new appendix to the report that comments on all studies mentioned here.

257. Kidney-Stones-Draft-Appendi-C (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/kidney-stones-draft-appendi-c.xlsx
     January 01, 2024 - to followups or dropouts Some concerns No information about blinding; ITT analysis not specifically mentioned … whether the N analyzed (384) represents all who were randomized; missing data are not specifically mentioned … concealment was NR Yes None Yes None Probably no None NA None NA None Probably yes ITT not specifically mentioned … None No None Some concerns No information about allocation concealment No None NI Not specifically mentioned … None Probably no None No None NA None NA None Low None NI No prespecified protocol or analysis plan mentioned

258. Disposition of Comments_Comparative Effectiveness Review No. 267: ADHD Diagnosis and Treatment in Children and Adolescents (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-267-adhd-disposition-comments.pdf
     March 25, 2024 - Support strengths and work on weaknesses ALL OF THE ABOVE MENTIONED TOOLS AND SKILLS ARE PRACTISED … Evidence-Based Practice American Occupational Therapy Association Abbreviations and Acronyms As mentioned … Does this report describe both the problem and evidence in a way that you could understand I mentioned

259. CER 220: Disposition of Comments Report for Comparative Effectiveness of Analgesics To Reduce Acute Pain in the Prehospital Setting (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-220-disposition-comments-analgesics-prehospital-setting.pdf
     September 03, 2019 - Though mentioned, there would be value on clearly defining what resources would be required to ensure … lower rates of respiratory depression, which were cited as some of the downsides of opioids) As mentioned

260. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/diabetic-neuropathy-disposition-170707.pdf
     March 24, 2017 - TEP #2 Results _KQ2 Minor points: The Griebeler sys rev should be referenced the first time it is mentioned